A second clinical trial, conducted by Diabetes TrialNet and the Immune Tolerance Network, used higher doses of IL-2 in combination with the inhibitor of the mammalian target of rapamycin (mTOR), rapamycin. Here, MTOR is linked to diabetes mellitus.